Merus NV Investor Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Merus investor call. I would now like to turn the call over to Kathleen Farren, Investor Relations, Corporate Communications. Please go ahead.
Good evening from Orlando. Thank you for joining our call today. Tonight, we will be discussing the data presented in the Oral Plenary session of this year's American Association for Cancer Research or AACR annual meeting. The slide presentation is available on our website at www.merus.nl.
On this call, we will also make certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about our future expectations and plans and events and circumstances, including about finances, intellectual property, projections about Merus's clinical development for 2023 and beyond, and timing for plans and for meeting clinical and regulatory anticipated milestones related to petosemtamab and our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |